Article: Geron Corporation Announces Study Results Demonstrating the Utility of Telomerase Promoter-based therapies for cancer.

Business Editors and Health/Medical Writers

MENLO PARK, Calif.--(BW HealthWire)--April 5, 2001

Geron Corporation (Nasdaq:GERN) announced today the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells. The research, described in the April 4 issue of Gene Therapy, shows that the cloned promoter of the human telomerase reverse transcriptase (hTERT) gene can drive the selective expression of therapeutic genes in cancer cells in vitro and in vivo, while remaining inactive in normal somatic cells and tissues.

The research takes advantage of the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!